重组人生长激素治疗生长激素缺乏症对肺功能的影响

Effect of the Recombinant Human Growth Hormone Therapy on Pulmonary Function in Patients with Growth Hormone Deficiency

目的研究重组人生长激素 (rhGH)治疗生长激素缺乏症 (GHD)对肺功能的影响。 方法 10例GHD伴促性腺激素缺乏的男性患儿 ,年龄 15 .6± 3 .2岁 ,身高年龄 (HA) 8.82± 1.81岁 ,给予rhGH(健高宁 )治疗 ,剂量为 0 .1IU·kg-1·d-1,疗程 12个月 ,观察治疗前 ,治疗后 6个月 ,12个月肺活量 (VC)和最大通气量 (MVV)变化 ,并和预计数比较。 结果 10例GHD患儿经 12个月的rhGH治疗身高增长明显。HA增加 2 .1岁 ,年生长速率 (HV)比治疗前提高 4倍 (P <0 .0 0 1)。VC ,MVV治疗后 12个月均比治疗前明显增加 ,两者差异皆具显著性 (P <0 .0 5 )。但患儿治疗前后的VC ,MVV占预计数百分比差异无显著性 ( P >0 .0 5 )。 结论rhGH对GHD患者有明显的促线性生长和发育作用 ,随体表面积的增加肺功能有相应的改善。

Objective To evaluate the effect of recombinant human growth hormone (rhGH) therapy on pulmonary function in patients with growth hormone deficiency (GHD). 10 GHD patients (age 15.6±3.2 years, height age 8.82±1.81 years) received imported rhGH (Genotropin, Pharmacia) 0.1 IU·kg -1 ·d -1 for 12 months. Vital capacity (VC) and Maximal ventilatory volume (MVV) were measured before and 6, 12 months after with rhGH treatment. The effects of rhGH on the increase of linear growth is significant (P<0.001),height age(HA) increased 2.1 years, height velocity (HV) increased from 2.89±0.6cm/a (before treatment) to 11.08±2.15cm/a (after treatment) and the differences is highly significant (P<0.001). Before and after 12 months with rhGH treatment, VC and MVV had significantly increased (P<0.05). Whereas the predicted percentages (VC, MVV) did not show any significant change. rhGH promoted significantly growth and development in GHD patients, the pulmonary function improved proportionally to the body surface area increment.